Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paroxetine + zolpidem is a combination of two pharmaceutical drugs used together, primarily studied for the treatment of primary insomnia. Paroxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant, while zolpidem is a non-benzodiazepine hypnotic agent that acts as an agonist at the gamma-aminobutyric acid (GABA) A receptor complex. The combination has been shown to be more effective than zolpidem alone in improving sleep maintenance and reducing early morning awakenings in patients with primary insomnia. However, combining these agents can result in additive central nervous system depression and impairment of psychomotor skills[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paroxetine + zolpidem.